Decoding liver cancer immune evasion with advanced testing
Part of Cancer, Digestive system clinical trials.
This trial studies liver cancer tissue to understand how the tumor hides from the immune system. The goal is to use this knowledge to improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of liver cancer (hepatocellular carcinoma) confirmed by biopsy or imaging.
- You need to have a fresh tissue sample from a liver cancer biopsy or surgery, or an archived tumor sample available for testing.
- You must be able to understand and sign a consent form.
- Your hepatitis B and C status must be known, including specific lab results and any past treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.